Metabolic
Pemvidutide
Also called ALT-801
per administration
It has been used in people, but no trial has settled how much or how often.
Quick start
Pemvidutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 1.2–2.4 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~25.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Pemvidutide describe 1.2–2.4 mg per administration. Descriptive only, not a recommendation.
Multi-day, consistent with once-weekly administration; precise human figures are not well characterized.
A GLP-1 and glucagon dual receptor agonist studied for weight reduction in phase 1/2 research. No confirmed dose-ranging publication fixes a subcutaneous schedule, so no schedule table is shown.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Pemvidutide (ALT-801) early-phase program (Altimmune)Weekly subcutaneous GLP-1/glucagon dual agonist in early-phase weight research; no dose-ranging trial has fixed a schedule in published form.